e-Drug3D

2023

SOTORASIB

INN
SOTORASIB

cas 2296729-00-3

CLASS

ANTINEOPLASTIC
TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
INHIBITOR OF THE RAS GTPASE FAMILY
COVALENT DRUG

ROUTE (list)

ORAL

ATC code

L01XX73

PK parameters

Tmax 1 HOUR
VD 211 LITER
Cl 26.2 LITER / HOUR
PPB 89 PERCENT
t1/2 5 HOUR

Solubility

0.03 MILLIGRAM PER MILLILITER

Target

TARGET KRAS(G12C)

DrugCentral

GTPase KRas UNIPROT P01116 KRAS

Download SDF file

Pyrido[2,3-d]pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-, (1R)-

Formula:
C30H30F2N6O3

Calculated chemical properties:

MW 560.60
NB_atoms 41
XLogP 4.48
PSA 86.069
NB_HD 1
NB_HA 9
fsp3 0.30
Lipinski(0=no;1=yes) 0

FDA
NDA 214665 (label) INN (SOTORASIB) LUMAKRAS (AMGEN INC) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY